PHASE 1/2A ADMIRAL STUDY (UNITED KINGDOM)

Stoke Therapeutics Presents Data from the Phase 1/2a MONARCH Study of STK-001 in Children and Adolescents with Dravet Syndrome at the American Epilepsy Society (AES) 2021 Annual Meeting

Retrieved on: 
Friday, December 3, 2021
Biotechnology, Pharmaceutical, Teens, General Health, Health, Children, Consumer, Other Health, Dravet Syndrome, STK-001, Phase 1/2a MONARCH Study (United States), Phase 1/2a ADMIRAL Study (United Kingdom), TANGO, Stoke Therapeutics, DRAVET SYNDROME, STK-001, PHASE 1/2A MONARCH STUDY (UNITED STATES), PHASE 1/2A ADMIRAL STUDY (UNITED KINGDOM), TANGO, STOKE THERAPEUTICS

22.7% (5/22) of patients had a serious treatment-emergent adverse event (SAE), none of which were related to study drug.

Key Points: 
  • 22.7% (5/22) of patients had a serious treatment-emergent adverse event (SAE), none of which were related to study drug.
  • All patients ages 2-12 (n=7) experienced a reduction from baseline in convulsive seizure frequency measured from Day 29 to Day 84.
  • STK-001 is designed to target the underlying cause of Dravet syndrome to potentially address both seizures and non-seizure comorbidities, said Barry Ticho, M.D., Ph.D., Chief Medical Officer of Stoke Therapeutics.
  • Compared with the general epilepsy population, people living with Dravet syndrome have a higher risk of sudden unexpected death in epilepsy, or SUDEP.

Stoke Therapeutics Announces Presentations from the Company’s Dravet Syndrome Program at the American Epilepsy Society 2021 Annual Meeting

Retrieved on: 
Friday, November 19, 2021
FDA, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Linda, 2021 Essex County Council election, Observational study, Language, Adolescence, Death, Diagnosis, Cerebrospinal fluid, Lurie Children's Hospital, Pharmacokinetics, Prognosis, Risk, Neurology, Stoke, Â, Associate, OLE, Intellectual disability, Movement, PK, AES, Seizure, DS, American Epilepsy Society, Hospital, ASO, SCN1A, Caregiver, Lists of diseases, Autonomic nervous system, SUDEP, Dravet syndrome, Development of the nervous system, Annual general meeting, FDA, Medicine, Therapy, MB, Quality of life, Mayo Clinic, NHP, Safety, Ann, Government budget balance, Plasma, Feinberg School of Medicine, Nasdaq, Sleep, European Journal of Paediatric Neurology, Disease, Pharmaceutical industry, Communications satellite, Vaccine, Dravet Syndrome, STK-001, Phase 1/2a MONARCH Study (United States), Phase 1/2a ADMIRAL Study (United Kingdom), TANGO, Stoke Therapeutics, DRAVET SYNDROME, STK-001, PHASE 1/2A MONARCH STUDY (UNITED STATES), PHASE 1/2A ADMIRAL STUDY (UNITED KINGDOM), TANGO, STOKE THERAPEUTICS

At Stoke, our goal is to develop the first medicine to target the underlying cause of Dravet syndrome, a severe and progressive genetic epilepsy, said Barry Ticho, M.D., Ph.D., Chief Medical Officer of Stoke Therapeutics.

Key Points: 
  • At Stoke, our goal is to develop the first medicine to target the underlying cause of Dravet syndrome, a severe and progressive genetic epilepsy, said Barry Ticho, M.D., Ph.D., Chief Medical Officer of Stoke Therapeutics.
  • Compared with the general epilepsy population, people living with Dravet syndrome have a higher risk of sudden unexpected death in epilepsy, or SUDEP.
  • STK-001 is an investigational new medicine for the treatment of Dravet syndrome currently being evaluated in ongoing clinical trials.
  • The Companys first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy.

Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates

Retrieved on: 
Monday, November 8, 2021
Other Health, Research, General Health, Pharmaceutical, Optical, Oncology, Infectious Diseases, Hospitals, Genetics, Science, FDA, Health, Seizure, TANGO, Haploinsufficiency, Safety, Quality of life, Language, OPA1, Contract, Therapy, ASO, OLE, SCN1A, Medicine, Epilepsy, Caregiver, Clinical trial, Intellectual disability, Asos, Movement, RNA, Disease, RNA splicing, Technology, Gene, Prognosis, Lists of diseases, Government budget balance, Dravet syndrome, Research, Autonomic nervous system, SUDEP, American Epilepsy Society, Protein, ADOA, Patient, Company, Annual general meeting, Collection, Diagnosis, Death, AES, Nasdaq, Sleep, Risk, FDA, Targeted molecular therapy for neuroblastoma, Natural history, Vaccine, Pharmaceutical industry, Animal, Cryptocurrency, TANGO, Dravet Syndrome, STK-001, Phase 1/2a MONARCH Study (United States), Phase 1/2a ADMIRAL Study (United Kingdom), Autosomal Dominant Optic Atrophy (ADOA), STK-002, Stoke Therapeutics, TANGO, DRAVET SYNDROME, STK-001, PHASE 1/2A MONARCH STUDY (UNITED STATES), PHASE 1/2A ADMIRAL STUDY (UNITED KINGDOM), AUTOSOMAL DOMINANT OPTIC ATROPHY (ADOA), STK-002, STOKE THERAPEUTICS

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today reported financial results for the third quarter of 2021 and provided business updates.

Key Points: 
  • Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today reported financial results for the third quarter of 2021 and provided business updates.
  • The Company has nominated STK-002 as the clinical candidate for the treatment of ADOA, a severe and progressive optic nerve disorder.
  • The Company is on track to initiate the collection of natural history data of people living with ADOA by year-end.
  • Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines.

Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates

Retrieved on: 
Tuesday, August 10, 2021
Health, Genetics, Clinical Trials, Research, Science, Optical, Biotechnology, ADOA, CSF, Patient, FDA, Targeted molecular therapy for neuroblastoma, Brain, Research, Phase, Quality of life, Nasdaq, Lists of diseases, United Kingdom, PK, TANGO, Safety, Association, Disease, Diagnosis, SCN1A, Seizure, Cell, Natural history, Society, Contract, OLE, Protein, OPA1, Severe cognitive impairment, Technology, Annual general meeting, Therapy, SAD, Association for Research in Vision and Ophthalmology, The Association, MAD, RNA, Company, Pharmacokinetics, Dravet syndrome, Gene, Haploinsufficiency, Asos, ASO, ARVO, Vaccine, Pharmaceutical industry, Medical imaging, Cryptocurrency, Animal, TANGO, STK-001, Phase 1/2a MONARCH Study (United States), Phase 1/2a ADMIRAL Study (United Kingdom), Dravet Syndrome, Autosomal Dominant Optic Atrophy (ADOA), Stoke Therapeutics, TANGO, STK-001, PHASE 1/2A MONARCH STUDY (UNITED STATES), PHASE 1/2A ADMIRAL STUDY (UNITED KINGDOM), DRAVET SYNDROME, AUTOSOMAL DOMINANT OPTIC ATROPHY (ADOA), STOKE THERAPEUTICS

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines, today reported financial results for the second quarter of 2021 and provided business updates.

Key Points: 
  • Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines, today reported financial results for the second quarter of 2021 and provided business updates.
  • During the first half of 2021, the Stoke team laid the groundwork for important clinical milestones in the second half of this year, said Edward M. Kaye, M.D., Chief Executive Officer of Stoke Therapeutics.
  • Lead optimization on track to identify a clinical candidate for the treatment of ADOA by the end of 2021.
  • Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines.

Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates

Retrieved on: 
Monday, May 10, 2021
Biotechnology, Health, Genetics, Pharmaceutical, Clinical trials, Medicine, Health sciences, Health, Medical terminology, Clinical research, Clinical trials, Medical statistics, Clinical endpoint, Seizure, Disease, TANGO, STK-001, Phase 1/2a MONARCH Study (United States), Phase 1/2a ADMIRAL Study (United Kingdom), Dravet Syndrome, Autosomal Dominant Optic Atrophy (ADOA), Stoke Therapeutics, TANGO, STK-001, PHASE 1/2A MONARCH STUDY (UNITED STATES), PHASE 1/2A ADMIRAL STUDY (UNITED KINGDOM), DRAVET SYNDROME, AUTOSOMAL DOMINANT OPTIC ATROPHY (ADOA), STOKE THERAPEUTICS

Together, we believe these studies will provide meaningful data to inform future development of STK-001,\xe2\x80\x9d said Edward M. Kaye, M.D., Chief Executive Officer of Stoke Therapeutics.

Key Points: 
  • Together, we believe these studies will provide meaningful data to inform future development of STK-001,\xe2\x80\x9d said Edward M. Kaye, M.D., Chief Executive Officer of Stoke Therapeutics.
  • In these cases, the mutated gene does not produce its share of protein, so the body does not function normally.
  • Stoke also intends to measure non-seizure aspects of the disease, such as quality of life, as secondary endpoints.
  • Stoke also intends to measure non-seizure aspects of the disease, such as overall clinical status and quality of life, as secondary endpoints.